Catalent Inc/ US1488061029 /
20/09/2024 22:10:00 | Chg. -0.11 | Volume | Bid02:00:00 | Ask02:00:00 | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
60.00USD | -0.18% | 3.54 mill. Turnover: 154.86 mill. |
59.33Bid Size: 900 | 61.17Ask Size: 100 | 10.89 bill.USD | - | - |
GlobeNewswire
28/05
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of...
GlobeNewswire
17/05
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of...
GlobeNewswire
14/05
Passage Bio Reports First Quarter 2024 Financial Results and Provides Recent Business Highlights
GlobeNewswire
08/05
Siren Biotechnology and Catalent Enter Partnership for Manufacturing of AAV Gene Therapies for Cance...
GlobeNewswire
26/04
TAKE ACTION: The M&A Class Action Firm Launches Legal Inquiry for the Merger – CTLT, MGRC, CHRD, HRT
GlobeNewswire
11/04
Robbins LLP is Investigating the Acquisition of Catalent, Inc. (CTLT) by Novo Holdings
GlobeNewswire
04/04
TAKE ACTION: The M&A Class Action Firm Launches Legal Inquiry for the Merger – NS, CTLT, SCX, EVBG
GlobeNewswire
07/03
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Catalent, Inc. -...
GlobeNewswire
01/03
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of...
GlobeNewswire
01/03
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of...
GlobeNewswire
28/02
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Catalent, Inc. -...